Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06607549 · ClinicalTrials.gov registry record · Phase 1
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
A Phase 1 study of Central Nervous System Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06607549: Recruiting Phase 1 study of Central Nervous System Lymphoma, sponsored by University of Utah.
NCT06607549 is a Phase 1 study of Central Nervous System Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 12 participants, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06607549, a Phase 1 study of Central Nervous System Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
Primary Outcome
Maximum Tolerated Dose (MTD): MTD is defined as the highest dose under consideration that has an estimated DLT probability below 25% based upon the Bayesian optimal interval design. The MTD will be decided based on the BOIN decision rules set for phase 1a portion of the study.
Conditions Studied
Interventions
- DRUG Loncastuximab tesirine and rituximab (Lonca-R)
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
What NCT06607549 shows while recruiting
NCT06607549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Loncastuximab tesirine and rituximab (Lonca-R) is the first listed.
NCT06607549 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06607549 about?
NCT06607549 is a clinical study titled "Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)". The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
What is the current status of trial NCT06607549?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-03-18. Estimated completion is 2030-11.
What conditions does trial NCT06607549 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma.
What interventions are being tested in trial NCT06607549?
The interventions under investigation include: Loncastuximab tesirine and rituximab (Lonca-R) (DRUG).
Who is sponsoring clinical trial NCT06607549?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06607549 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06607549's enrollment target sits among peer trials
12 14th of 14 higher than 1 of 14 other Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Acalabrutinib in CNSL
ACTIVE NOT RECRUITING · Phase 1
-
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
COMPLETED · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI